Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Antiviral Res. 2017 Apr 23;143:162–175. doi: 10.1016/j.antiviral.2017.04.011

Figure 7. In vivo efficacy of rapamycin, high dose study.

Figure 7

Female BALB/c mice, 6–8 weeks of age, were randomly distributed into treatment groups consisting of 10 mice per group. Mice were infected via the subcutaneous route with a high dose of RVFV ZH501 (1,500 PFU/mouse). Health scores and weights were assessed daily. The endpoints were day 21, death, or euthanasia. The survival curve is shown in panels A, % of weight maintained over the course of the study is shown in panel B, and the clinical scoring chart for the vehicle control group and rapamycin treated group are shown in panel C. Log-rank (Mantel-Cox) test was used to determine statistical significance of the survival curve and a two-way ANOVA analysis was used to evaluate the change in weight loss, *p-value ≤ 0.05.